Express Pharma

MARCH 16, 2025

First, advanced research and development (R&D) and biologics will be critical. To move from generics to novel drug development, Indian companies must invest heavily in R&D for innovative therapies like biosimilars, cell and gene therapies, and specialty drugs. and Europe.

Biosimilars 110

Biosimilars Insurance Coverage and Processing Pharmaceutical Companies Pharmaceutical Companies 110

Pharmaceutical Technology

FEBRUARY 23, 2023

Ranibizumab biosimilar is under clinical development by Generium and currently in Phase III for Wet (Neovascular / Exudative) Macular Degeneration. GlobalData’s report assesses how Ranibizumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Biosimilars 52

Biosimilars Diabetes Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

JUNE 24, 2021

Lucentis has been approved by the FDA since 2006 for wet AMD and is a big earner for both Roche and Novartis, who share rights to the product with Roche selling the drug in the US and Novartis selling it in Europe and other markets. billion in US sales, while Novartis’ sales of the drug topped $1.9 billion in 2020 revenues.

Diabetes 95

Diabetes Biosimilars Drug Development 95

Express Pharma

SEPTEMBER 6, 2023

According to the World Health Organisation (WHO), an estimated two billion people across the world do not have access to essential medicines for life threatening diseases like cancer, AIDS and even autoimmune diseases like Type 1 diabetes. The post Is India capable of ensuring equitable access to biopharmaceuticals?

Insurance Coverage and Processing 59

Insurance Coverage and Processing Biosimilars Generic Medicine Drug Pricing 59

Pharma Marketing Network

FEBRUARY 27, 2025

For example, a pharma company launching a new biosimilar for rheumatoid arthritis can publish a whitepaper detailing clinical comparisons with the branded biologic. Behind-the-scenes research lab videos showcasing drug development. Chatbots answering FAQs on drug safety and usage.

Biosimilars 52

Biosimilars Communication Diabetes Drug Development 52

PharmaShots

FEBRUARY 27, 2023

As a renowned chemist, Dr. Senanayake discussed the need to adopt green chemistry in the process of drug development for cost reduction, timely innovation, and generating less waste than the standard process. To provide the audience with an Indian viewpoint, the presenters pointed out the country's requirements for biosimilar PV.

Biosimilars 40

Biosimilars Diabetes Packaging Hospitals 40

Express Pharma

JULY 3, 2023

How is the industry’s approach to drug development transforming? How is Waters aiding advancements in drug development? A central aim in drug development is to create new molecular entities into commercially viable drugs useful in managing diseases. What are the imperatives that led to this change?

Biosimilars 95

Biosimilars Drug Development Generic Medicine Diabetes 95